Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 19 Lymphoma 5 Lung Neoplasms 5 Multiple Myeloma 4 Lymphoma, Large-Cell, Anaplastic 4 Neuroblastoma 3 Neoplasms 2 Hematologic Neoplasms 2 Carcinoma 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumors 1 Neurofibromatosis 2 1 Colorectal Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Lobular 1 Carcinoma, Large Cell 1 Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1 Advanced Cancer 1 Adenocarcinoma of Lung 1 Adenocarcinoma 1 ALK-positive NSCLC 1 ALK or ROS1-positive NSCLC 1

Interventions

Bevacizumab 3 Lapatinib 2 vistusertib 1 brolucizumab 1 aflibercept 1 Vascular Endothelial Growth Factor A 1 Sunitinib 1 HDAC-42 1 Everolimus 1 Crizotinib 1 Axitinib 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Neurofibromatosis 2 × Crizotinib × Clear all

NCT04283669 2026-03-13

NF110

University of Alabama at Birmingham

Phase 2 Completed

12 enrolled 5 charts

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡